35批次药品不符合规定被通报，科伦药业、华鲁制药榜上有名

Core Viewpoint - The National Medical Products Administration announced that 35 batches of drugs produced by 29 companies do not meet regulatory standards, including two batches of sodium bicarbonate injection from Sichuan Kelun Pharmaceutical Co., Ltd. [1] Group 1: Regulatory Issues - The two batches of sodium bicarbonate injection from Sichuan Kelun Pharmaceutical were found non-compliant regarding pH value, insoluble particles, and visible foreign matter [1][2] - The inspection was conducted by the Anhui Food and Drug Inspection Institute [1][2] Group 2: Company Performance - In the first three quarters of the year, Kelun Pharmaceutical reported total revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% [3] - The company has experienced a continuous decline in net profit for four consecutive quarters [3][4] - In November, Kelun Pharmaceutical received a registration notice for a short-term financing bond with a registration limit of 4 billion yuan, valid for two years [3] Group 3: Market Data - As of December 4, Kelun Pharmaceutical's stock closed at 34.10 yuan per share, with a total market capitalization of 54.494 billion yuan [3][5] - The stock has seen a price increase of 0.29% on that day [5]